Glycopyrronium for chronic obstructive pulmonary disease: evidence and rationale for use from the GLOW trials. (December 2014)

• Record Type: Journal Article
• Authors: Miravitlles, Marc; Beeh, Kai-Michael; Altman, Pablo
• Is Part Of: Clinical investigation. Volume 4:Number 12(2014)
• Page Start: 1095
• Page End: 1111
• Publication Date: 2014-12
• Subjects: chronic obstructive pulmonary disease -- clinical study -- efficacy -- glycopyrronium -- long-acting muscarinic antagonist -- safety -- tiotropium; Drugs -- Testing -- Periodicals; Drug development -- Periodicals; Clinical trials -- Periodicals; 615.580724
• DOI: 10.4155/cli.14.89
• Languages: English
• ISSNs: 2041-6806

Abstract

The clinical development of the long-acting muscarinic antagonist bronchodilator glycopyrronium (Seebri ® Breezhaler ® inhalation powder) in the GLOW (glycopyrronium bromide in chronic obstructive pulmonary disease airways) series of studies showed that, compared with placebo, once-daily glycopyrronium provided 24-h bronchodilation, improved symptoms and health status and reduced the risk and rate of moderate or severe exacerbations. Glycopyrronium also reduced dynamic hyperinflation and increased exercise tolerance. Compared with the long-acting muscarinic antagonist tiotropium, glycopyrronium had a similar effect on clinical outcomes with a faster onset of action. Added to the long-acting β2 -agonist bronchodilator indacaterol, glycopyrronium had a greater bronchodilator effect and improved dyspnea versus indacaterol alone. There were no significant safety issues in the GLOW studies. Glycopyrronium is a useful addition to the treatments for chronic obstructive pulmonary disease.